648 results on '"Friberg, Lena E."'
Search Results
152. Colistin Resistance Development Following Colistin-Meropenem Combination Therapy Versus Colistin Monotherapy in Patients With Infections Caused by Carbapenem-Resistant Organisms.
153. Advanced methods for dose and regimen finding during drug development:Summary of the EMA /EFPIA workshop on dose finding (London 4-5 December 2014)
154. Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia
155. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration
156. Erratum to: Warfarin dose prediction in children using pharmacometric bridging – comparison with published pharmacogenetic dosing algorithms
157. A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients
158. A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat
159. Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?
160. Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment
161. Reply to Prim et al., “Is Colistin Susceptibility Testing Finally on the Right Track?”
162. Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli
163. Colistin Is Extensively Lost during Standard In Vitro Experimental Conditions
164. Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats
165. Assessment of early combination effects of colistin and meropenem againstPseudomonas aeruginosaandAcinetobacter baumanniiin dynamic time-kill experiments
166. Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic Pharmacokinetic–Pharmacodynamic Modeling for Evaluation of Treatments against Chronic Pseudomonas aeruginosaLung Infections
167. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
168. A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients.
169. Colistin Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate (CMS) in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration (CVVHDF)
170. A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
171. Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer
172. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol
173. A pharmacokinetic–pharmacodynamic (PKPD) model based onin vitrotime–kill data predicts thein vivoPK/PD index of colistin
174. Dynamic interaction of colistin and meropenem on a WT and a resistant strain ofPseudomonas aeruginosaas quantified in a PK/PD model
175. Pharmacometrics and Systems Pharmacology 2030.
176. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients
177. The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.
178. Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data.
179. Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T‑Cell Bispecific in Combination with Anti‑PD‑L1.
180. A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants
181. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients
182. Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response
183. Performance of Nonlinear Mixed Effects Models in the Presence of Informative Dropout
184. Model‐based assessment of neutrophil‐mediated phagocytosis and digestion of bacteria across in vitro and in vivo studies.
185. Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring.
186. Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments.
187. Bayesian Hierarchical Modeling with Markov Chain Monte Carlo Methods
188. Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling
189. Pharmacokinetic-Pharmacodynamic Modelling of Anticancer Drugs : Haematological Toxicity and Tumour Response in Hollow Fibres
190. Publisher Correction: Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance.
191. A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform
192. Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs
193. CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity
194. A pharmacogenetic model predicting low paclitaxel clearance based on the DMET platform.
195. Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration
196. A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.
197. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety
198. A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
199. Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic‐pharmacodynamic models.
200. Influence of Smoking on the Pharmacokinetics and Toxicity Profiles of Taxane Therapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.